​

ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ACAD Stock Forecast

ACADIA Pharmaceuticals (ACAD) stock forecast, based on 32 Wall Street analysts, predicts a 12-month average price target of $25.60, with a high of $32.00 and a low of $20.00. This represents a 14.80% increase from the last price of $22.30.

$10 $15 $20 $25 $30 $35 High: $32 Avg: $25.6 Low: $20 Last Closed Price: $22.3

ACAD Stock Rating

ACADIA Pharmaceuticals stock's rating consensus is Buy, based on 32 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (68.75%), 9 Hold (28.12%), 1 Sell (3.12%), and 0 Strong Sell (0.00%).

Buy
Total 32 1 9 22 Strong Sell Sell Hold Buy Strong Buy

ACAD Price Target Upside V Benchmarks

TypeNameUpside
StockACADIA Pharmaceuticals14.80%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts347
Avg Price Target$28.67$27.00$25.57
Last Closing Price$22.30$22.30$22.30
Upside/Downside28.57%21.08%14.66%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25676-120
May, 25667-120
Apr, 25667-120
Mar, 25667-120
Feb, 25666-119
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 20, 2025Sean LaamanMorgan Stanley$24.00$21.6910.65%7.62%
May 19, 2025Andrew FeinH.C. Wainwright$32.00$21.9845.59%43.50%
May 19, 2025Ami FadiaNeedham$30.00$21.9836.49%34.53%
Apr 28, 2025UBS$22.00$14.6650.07%-1.35%
Jan 03, 2025Yatin SunejaGuggenheim$20.00$18.498.17%-10.31%
Aug 07, 2024Jeffrey HungMorgan Stanley$20.00$18.856.10%-10.31%
Jun 26, 2024Keith TapperBMO Capital$31.00$15.50100.00%39.01%
May 09, 2024Andrew FeinH.C. Wainwright$27.00$17.1357.62%21.08%
May 09, 2024Joel BeattyRobert W. Baird$28.00$17.1363.46%25.56%
May 09, 2024Uy EarMizuho Securities$21.00$17.1322.59%-5.83%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 20, 2025Deutsche BankBuyupgrade
May 16, 2025BMO CapitalOutperformOutperformhold
May 16, 2025OppenheimerPerformPerformhold
May 16, 2025NeedhamBuyBuyhold
Jan 03, 2025GuggenheimBuyNeutraldowngrade
Oct 17, 2024GuggenheimBuyBuyhold
Oct 10, 2024UBSBuyBuyhold
Aug 07, 2024RBC CapitalEqual-WeightEqual-Weighthold
Aug 07, 2024Morgan StanleyOverweightEqual-Weightdowngrade
Jun 26, 2024BMO CapitalBuyOutperforminitialise

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.79$-1.05$-1.34$-0.37$1.37----
Avg Forecast$-1.84$-1.02$-1.32$-0.36$0.72$0.75$1.12$1.67$2.18
High Forecast$-1.70$-0.94$-1.25$-0.07$1.21$1.19$2.27$2.78$2.32
Low Forecast$-1.94$-1.08$-1.42$-0.47$0.43$0.24$0.43$0.11$2.07
Surprise %-2.72%2.94%1.52%2.78%90.28%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$441.75M$484.14M$517.24M$726.44M$957.80M----
Avg Forecast$443.75M$487.98M$514.79M$719.17M$969.65M$1.05B$1.17B$1.30B$1.44B
High Forecast$462.99M$509.14M$546.26M$723.91M$975.90M$1.09B$1.18B$1.31B$1.51B
Low Forecast$417.17M$458.75M$496.61M$709.72M$964.06M$1.02B$1.17B$1.29B$1.39B
Surprise %-0.45%-0.79%0.47%1.01%-1.22%----

Net Income Forecast

$-350M $-180M $-10M $160M $330M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-281.58M$-167.87M$-215.97M$-61.29M$226.45M----
Avg Forecast$-257.72M$-187.72M$-252.14M$-61.29M$128.51M$134.26M$208.81M$282.56M$357.29M
High Forecast$-206.17M$-150.18M$-201.71M$-49.03M$197.58M$194.99M$371.62M$455.51M$379.72M
Low Forecast$-309.26M$-225.27M$-302.57M$-73.54M$70.93M$38.68M$71.02M$18.15M$339.05M
Surprise %9.26%-10.58%-14.34%-76.22%----

ACAD Forecast FAQ

Is ACADIA Pharmaceuticals stock a buy?

ACADIA Pharmaceuticals stock has a consensus rating of Buy, based on 32 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 9 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that ACADIA Pharmaceuticals is a favorable investment for most analysts.

What is ACADIA Pharmaceuticals's price target?

ACADIA Pharmaceuticals's price target, set by 32 Wall Street analysts, averages $25.6 over the next 12 months. The price target range spans from $20 at the low end to $32 at the high end, suggesting a potential 14.80% change from the previous closing price of $22.3.

How does ACADIA Pharmaceuticals stock forecast compare to its benchmarks?

ACADIA Pharmaceuticals's stock forecast shows a 14.80% upside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for ACADIA Pharmaceuticals over the past three months?

  • June 2025: 30.00% Strong Buy, 35.00% Buy, 30.00% Hold, 0% Sell, 5.00% Strong Sell.
  • May 2025: 30.00% Strong Buy, 30.00% Buy, 35.00% Hold, 0% Sell, 5.00% Strong Sell.
  • April 2025: 30.00% Strong Buy, 30.00% Buy, 35.00% Hold, 0% Sell, 5.00% Strong Sell.

What is ACADIA Pharmaceuticals’s EPS forecast?

ACADIA Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $0.75, marking a -45.26% decrease from the reported $1.37 in 2024. Estimates for the following years are $1.12 in 2026, $1.67 in 2027, and $2.18 in 2028.

What is ACADIA Pharmaceuticals’s revenue forecast?

ACADIA Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $1.05B, reflecting a 10.06% increase from the reported $957.8M in 2024. The forecast for 2026 is $1.17B, followed by $1.3B for 2027, and $1.44B for 2028.

What is ACADIA Pharmaceuticals’s net income forecast?

ACADIA Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $134.26M, representing a -40.71% decrease from the reported $226.45M in 2024. Projections indicate $208.81M in 2026, $282.56M in 2027, and $357.29M in 2028.